Literature DB >> 29608549

Budding Uninhibited by Benzimidazole-1 Insufficiency Prevents Acute Renal Failure in Severe Sepsis by Maintaining Anticoagulant Functions of Vascular Endothelial Cells.

Yutaka Matsubara1,2, Takuya Matsumoto1,3, Keiji Yoshiya1, Ayae Yoshida1, Seiichi Ikeda1, Tadashi Furuyama1, Yoshimichi Nakatsu4, Teruhisa Tsuzuki4, Masatoshi Nomura5, Yoshihiko Maehara1.   

Abstract

Severe sepsis is critical to health and can result in acute renal failure (ARF). Tissue factor (TF) and thrombomodulin (TM) play key roles in vascular endothelial functions by helping maintain microcirculation in the kidney. Budding uninhibited by benzimidazole-1 (Bub1) plays a role in Akt and JNK signaling, which control TF and TM, respectively. We hypothesized that Bub1 could control vascular endothelial function in sepsis. The aim of this study was to determine the role of Bub1 in septic ARF. We used Mouse cecum ligation and puncture (CLP) using low Bub1 expressing (Bub1) and wild-type (Bub1) mice in vivo and lipopolysaccharide (LPS) stimulation of human aortic endothelial cell (HAEC) in vitro. Bub1 mice had a higher survival rate after CLP than Bub1. Bub1 mice had more severe ARF after CLP than Bub1 with blood biochemical and pathological analyses. TF expression in Bub1 mice and control HAEC (control) significantly increased in the septic model compared with Bub1 and Bub1 silenced HAEC (siBub1). TM expression in the control significantly decreased after LPS stimulation compared with siBub1. Akt and JNK phosphorylation of siBub1 were attenuated after LPS stimulation. Associations of Bub1 with Akt or JNK after LPS stimulation of HAEC were detected using immunoprecipitation, suggesting that Bub1 is involved in the phosphorylation of Akt and JNK after LPS stimulation. Bub1 insufficiency attenuates TF expression and reduces TM suppression by blocking Akt and JNK phosphorylation, respectively, thus leading to the prevention of ARF and death caused by sepsis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29608549     DOI: 10.1097/SHK.0000000000001147

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  3 in total

1.  What's New in Shock, March 2019?

Authors:  Hongkuan Fan; Andrew J Goodwin
Journal:  Shock       Date:  2019-03       Impact factor: 3.454

2.  Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.

Authors:  Axel Rosell; Bernhard Moser; Yohei Hisada; Rukesh Chinthapatla; Grace Lian; Yi Yang; Matthew J Flick; Nigel Mackman
Journal:  Res Pract Thromb Haemost       Date:  2020-07-06

3.  Comprehensive analysis reveals a four-gene signature in colorectal cancer.

Authors:  Bin Zhao; Zheng Wan; Xiaohong Zhang; Yilin Zhao
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.